

Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-072024-0001020

**Date:** 21/08/2024

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

**Request**

Q1. How many patients were treated **in total, regardless of diagnosis**, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Q2. How many patients were treated for **severe asthma**, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Q3. How many patients were treated **by department** in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Q4. How many patients were treated for **Asthma** the following medicines in the 3 months between the start of April 2024 and end of June 2024?

*Please answer this question for ICS-LABA combination medicines e.g. Symbicort, Seretide and other branded or generic versions of the combination.*

**Response**

Q1. In the 3 months Apr24-Jun24, the following number of patients were issued with the listed treatments, **regardless of diagnosis**:

<i>Name of medicine</i>	<i>Number patients treated</i>
1.1 Benralizumab (Fasenra)	66
1.2 Dupilumab (Dupixent)	67
1.3 Mepolizumab (Nucala)	66
1.4 Omalizumab (Xolair)	53
1.5 Reslizumab (Cinqaero)	0
1.6 Tezepelumab (Tezspire)	25

Q2. In the 3 months Apr24-Jun24, the following number of patients were issued with the listed treatments, **for the named indications**:

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)	66	N/A	N/A	N/A
2.2 Dupilumab (Dupixent)	6	0	61	0
2.3 Mepolizumab (Nucala)	66	0	N/A	0
2.4 Omalizumab (Xolair)	23	0	N/A	30
2.5 Reslizumab (Cinqaero)	0	N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)	25	N/A	N/A	N/A

Q3. In the 3 months Apr24-Jun24, the following number of patients were issued with the listed treatments, **regardless of diagnosis**, from the named departments:

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)	66	0	0
3.2 Dupilumab (Dupixent)	6	61	0
3.3 Mepolizumab (Nucala)	66	0	0
3.4 Omalizumab (Xolair)	23	0	30
3.5 Reslizumab (Cinqaero)	0	0	0
3.6 Tezepelumab (Tezspire)	25	0	0

Q4. How many patients were treated for **Asthma** the following medicines in the 3 months between the start of April 2024 and end of June 2024?

**To provide the information you have requested the Trust would need to look at individual patient records which is exempt under Section 40 of the Act, Personal Information.**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
Page 2 of 3

FOI-072024-0001020

SK9 5AF

Tel: 0303 123 1113

[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**